TD Cowen on Centessa Pharmaceuticals (CNTA): 'ORX750 Opportunity in Sleep Disorders Is Meaningful'

March 5, 2025 8:57 AM EST Send to a Friend
TD Cowen analyst Stacy Ku reiterated a Buy rating on Centessa Pharmaceuticals (NASDAQ: CNTA).The analyst commented: "Mgmt Meeting Highlights: ORX750 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login